J David Warren, Ph.D., is an experienced researcher in the field of bioorganic and medicinal chemistry, who has placed several compounds into advanced preclinical development. His accomplishments include the development of methodology that allows for the total chemical synthesis of fully glycosylated proteins; the synthesis and application of new photostable fluorophores; the development of novel therapeutics for the treatment of Niemann-Pick type C (NPC) disease; the discovery of nucleoside analogs active against adenosine kinase; the discovery of selective inhibitors of HCN1 for the treatment of neuropathic pain; the discovery of novel PET tracers for imaging the chemokine receptor CXCR4; the identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancer; the discovery and development of inhibitors selective for mycobacterial versus human proteasomes; and the CURE-PRO platform, an innovative new approach to targeted protein degradation.

David is an Adjunct Associate Professor of Research in Biochemistry and former Director of the Milstein Chemistry Core Facility at Weill Cornell Medicine in New York City. He received his Ph.D. from Colorado State University, where he was awarded a graduate fellowship from Boehringer Ingelheim, and carried out postdoctoral studies under the tutelage of Dr. Samuel J. Danishefsky at the Memorial Sloan-Kettering Cancer Center as an NIH-supported fellow. He currently sits on the Scientific Advisory Board of Akelos, Inc., and is a scientific advisor for several small biopharmaceutical companies. He holds 10 issued US and international patents and has published over 48 peer-reviewed publications and book chapters.